ACM
ARCT icon

Atika Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Atika Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-714
Closed -$87K – 67
2014
Q2 		$87K Buy
+714
New +$86.2K 0.07% 61

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
EverPoint Asset Management
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Atika Capital Management's ARCT Position: Q3 2014 in Review

Atika Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2014, closing a stake of 714 shares — an estimated $87K sold.

Atika Capital Management first reported a position in ARCT in Q2 2014 and held it in 1 quarter. The position peaked at $87K in Q2 2014. 38 funds tracked by Wall St. Rank hold ARCT as of Q3 2014.

  • Atika Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Atika Capital Management sold 714 Arcturus Therapeutics shares in Q3 2014, an estimated $87K.
  • Atika Capital Management first reported a position in Arcturus Therapeutics in Q2 2014 and held it in 1 quarter.
  • Atika Capital Management's Arcturus Therapeutics position peaked at $87K in Q2 2014.
  • 38 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2014.

Based on Atika Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.